JAK inhibition shows two faces in prostate cancer

Nicholas J Brady¹, Christopher E Barbieri^{2

3

4}

Affiliations

¹ Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
² Department of Urology, Weill Cornell Medicine, New York, NY, USA. chb9074@med.cornell.edu.
³ Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA. chb9074@med.cornell.edu.
⁴ Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA. chb9074@med.cornell.edu.

Comment

Nicholas J Brady et al. Nat Cancer. 2022 Sep.

. 2022 Sep;3(9):1021-1023.

doi: 10.1038/s43018-022-00437-3.

Nicholas J Brady¹, Christopher E Barbieri^{2

3

4}

¹ Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
² Department of Urology, Weill Cornell Medicine, New York, NY, USA. chb9074@med.cornell.edu.
³ Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA. chb9074@med.cornell.edu.
⁴ Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA. chb9074@med.cornell.edu.

No abstract available

Comment on

Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance.
Deng S, Wang C, Wang Y, Xu Y, Li X, Johnson NA, Mukherji A, Lo UG, Xu L, Gonzalez J, Metang LA, Ye J, Tirado CR, Rodarte K, Zhou Y, Xie Z, Arana C, Annamalai V, Liu X, Vander Griend DJ, Strand D, Hsieh JT, Li B, Raj G, Wang T, Mu P. Deng S, et al. Nat Cancer. 2022 Sep;3(9):1071-1087. doi: 10.1038/s43018-022-00431-9. Epub 2022 Sep 5. Nat Cancer. 2022. PMID: 36065066 Free PMC article.